Medications

First cell-based gene therapy approved for multiple myeloma

Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T-cell therapy, was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, the agency announced Saturday.

Medical research

Metabolic response behind reduced cancer cell growth

Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells' ...

Oncology & Cancer

New insights into how the drug pomalidomide fights cancer

Multiple myeloma is a cancer of the white blood cells, and patients diagnosed with this disease commonly die within five years. Clinicians often treat multiple myeloma with the drug thalidomide and structurally similar drugs ...

Oncology & Cancer

New multiple myeloma therapy shows promise in preclinical study

A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of the ...

page 5 from 21